Further investigation into how noradrenergic degeneration interacts with AD pathology and contributes to cognitive decline, may help explain why some LLD are at heightened risk for dementia and may identify those most likely to benefit from noradrenergic-targeted treatments
In obesity, autophagy markers such as LC3-II and autophagosome formation are elevated, accompanied by reduced mTORC1 activity, particularly in visceral depots
The p21-derived tumor suppressor peptide from the C-terminal region can inactivate PCNA, which is necessary for cell proliferation [53]
[DOI] [PubMed] [Google Scholar] 190.Feher J., Kovacs B., Kovacs I., Schveoller M., Papale A., Balacco Gabrieli C
Bu ikayet...
The safety and efficacy of combining ferroptosis inhibitors with conventional LN therapies (e.g., glucocorticoids and immunosuppressants) are also untested